Determination of efavirenz in human dried blood spots by reversed-phase high-performance liquid chromatography with uv detection

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 203-208

  Hoffman, Justin T ^a   Rossi, Steven S ^b   Espina Quinto, Rowena ^a   Letendre, Scott ^c   Capparelli, Edmund V ^a,b,c  

^a Skagg's School of Pharmacy and Pharmaceutical Sciences   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

dried blood spots; dried plasma spots; efavirenz; HPLC

Indexed keywords

ACETONITRILE; EFAVIRENZ; POTASSIUM DIHYDROGEN PHOSPHATE;

ARTICLE; CALIBRATION; DRIED BLOOD SPOT TESTING; DRUG DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; VALIDATION STUDY;

ANTI-HIV AGENTS; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DRIED BLOOD SPOT TESTING; HUMANS; MASS SPECTROMETRY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84875194233     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827fb72b     Document Type: Article

References (22)

1. Majumdar TK, Howard DR. The use of dried blood spots for concentration assessment in pharmacokinetic evaluations. In: Bonate PL, Howard DR, eds. Pharmacokinetics in Drug Development. New York, NY: Springer Science; 2011: 91-114.
2. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963; 32: 338-343.
3. Edelbroek PM, van der Heijden J, Stolk LML. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009; 31: 327-336.
4. Mei JV, Alexander JR, Adam BW, et al. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr. 2001; 131: 1631S-1636S.
5. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem. 2009; 81: 1557-1563.
6. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 2010; 12: 290-293.
7. Emmons G, Rowland M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis. 2010; 2: 1791-1796.
8. Thomas A, Deglon J, Steimer T, et al. Online desorption of dried blood spots coupled to hydrophilic interaction/reversed-phase LC/MS/MS system for the simultaneous analysis of drugs and their polar metabolites. J Sep Sci. 2010; 33: 873-879.
9. Patel P, Mulla H, Tanna S, et al. Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch Dis Child. 2010; 95: 484-487.
10. Oandya HC, Spooner N, Mulla H. Dried blood spots, pharmacokinetic studies and better medicines for children. Bioanalysis. 2011; 3: 779-786.
11. Rowell V, Rowell FJ. Rapid enzyme-linked immunosorbent assay (ELISA) with a visual end-point for detecting quinine in urine, serum, and dried blood spots. Analyst. 1987; 112: 1437-1439.
12. Lejeune D, Souletie I, Houze S, et al. Simultaneous determination of monodesethylchloroquine, chloroquine, cycloguanil and proguanil on dried blood spots by reverse-phase liquid chromatography. J Pharm Biomed Anal. 2007; 43: 1106-1115.
13. Vu DH, Koster RA, Alffenaar JWC, et al. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J Chromatogr B Analyst Technol Biomed Life Sci. 2011; 879: 1063-1070.
14. Koal T, Burhenne H, Romling R, et al. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrum. 2005; 19: 2995-3001.
15. ter Heine R, Rosing H, van Gorp ECM, et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadruple mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 867: 205-212.
16. ter Heine R, Rosing H, van Gorp ECM, et al. Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal. 2009; 49: 393-400.
17. ter Heine R, Hillebrand MJX, Rosing H, et al. Quantification of the HIVintegrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal. 2009; 49: 451-458.
18. ter Heine R, Mulder JW, van Gorp ECM, et al. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir, and ritonavir in dried blood spot samples. Bioanalysis. 2011; 3: 1093-1097.
19. Boyd SD. A review of recommendations and treatment options regarding the management of HIV infection. Am J Health Syst Pharm. 2011; 68: 991-1001.
20. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15: 71-75.
21. Sustiva [Package Insert]. Princeton, NJ: Bristol-Meyers Squibb Company; 2012.
22. Almond LM, Hoggard PG, Edirisinghe D, et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother. 2005; 56: 738-744.